Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Since that time, though, demand for these products has declined, and that's resulted in lower revenue and a drop in the Pfizer share price. Right now, as an investor, you may be wondering if you ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Pfizer appoints former J&J executive to lead obesity drug development Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Since that time, though, demand for these products has declined, and that's resulted in lower revenue and a drop in the Pfizer share price. Right now, as an investor, you may be wondering if you ...